Caitlin A Moran1,2, Anandi N Sheth1,2, C Christina Mehta3, David B Hanna4, Deborah R Gustafson5, Michael W Plankey6, Wendy J Mack7, Phyllis C Tien8,9, Audrey L French10,11, Elizabeth T Golub12, Arshed Quyyumi1, Robert C Kaplan4, Ighovwerha Ofotokun1,2. 1. Department of Medicine, Emory University. 2. Department of Medicine, Grady Healthcare System. 3. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx. 5. Department of Neurology, State University of New York-Downstate, New York, New York. 6. Department of Medicine, Georgetown University Medical Center, Washington, District of Columbia. 7. Department of Preventive Medicine, University of Southern California, Los Angeles. 8. Department of Medicine, University of California-San Francisco. 9. Department of Veterans Affairs, San Francisco, California. 10. Department of Medicine, Stroger Hospital of Cook County. 11. Department of Medicine, Rush University Medical Center, Chicago, Illinois. 12. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV. DESIGN: Retrospective cohort study. METHODS: A total of 572 HIV-infected and 211 HIV-uninfected women enrolled in the Women's Interagency HIV Study underwent serial high-resolution B-mode carotid artery ultrasonography between 2004 and 2013 to assess carotid intima-media thickness (CIMT) and focal carotid artery plaques. We used multivariable linear and logistic regression models to assess the association of baseline high (≥3 mg/l) high-sensitivity (hs) CRP with baseline CIMT and focal plaques, and used multivariable linear and Poisson regression models for the associations of high hsCRP with CIMT change and focal plaque progression. We stratified our analyses by HIV status. RESULTS: Median (interquartile range) hsCRP was 2.2 mg/l (0.8-5.3) in HIV-infected, and 3.2 mg/l (0.9-7.7) in HIV-uninfected, women (P = 0.005). There was no statistically significant association of hsCRP with baseline CIMT [adjusted mean difference -3.5 μm (95% confidence interval:-19.0 to 12.1)] or focal plaques [adjusted odds ratio: 1.31 (0.67-2.67)], and no statistically significant association of hsCRP with CIMT change [adjusted mean difference 11.4 μm (-2.3 to 25.1)]. However, hsCRP at least 3 mg/l was positively associated with focal plaque progression in HIV-uninfected [adjusted rate ratio: 5.97 (1.46-24.43)], but not in HIV-infected [adjusted rate ratio: 0.81 (0.47-1.42)] women (P = 0.042 for interaction). CONCLUSION: In our cohort of women with similar CVD risk factors, higher baseline hsCRP is positively associated with carotid plaque progression in HIV-uninfected, but not HIV-infected, women, suggesting that subclinical CVD pathogenesis may be different HIV-infected women.
OBJECTIVE: HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV. DESIGN: Retrospective cohort study. METHODS: A total of 572 HIV-infected and 211 HIV-uninfected women enrolled in the Women's Interagency HIV Study underwent serial high-resolution B-mode carotid artery ultrasonography between 2004 and 2013 to assess carotid intima-media thickness (CIMT) and focal carotid artery plaques. We used multivariable linear and logistic regression models to assess the association of baseline high (≥3 mg/l) high-sensitivity (hs) CRP with baseline CIMT and focal plaques, and used multivariable linear and Poisson regression models for the associations of high hsCRP with CIMT change and focal plaque progression. We stratified our analyses by HIV status. RESULTS: Median (interquartile range) hsCRP was 2.2 mg/l (0.8-5.3) in HIV-infected, and 3.2 mg/l (0.9-7.7) in HIV-uninfected, women (P = 0.005). There was no statistically significant association of hsCRP with baseline CIMT [adjusted mean difference -3.5 μm (95% confidence interval:-19.0 to 12.1)] or focal plaques [adjusted odds ratio: 1.31 (0.67-2.67)], and no statistically significant association of hsCRP with CIMT change [adjusted mean difference 11.4 μm (-2.3 to 25.1)]. However, hsCRP at least 3 mg/l was positively associated with focal plaque progression in HIV-uninfected [adjusted rate ratio: 5.97 (1.46-24.43)], but not in HIV-infected [adjusted rate ratio: 0.81 (0.47-1.42)] women (P = 0.042 for interaction). CONCLUSION: In our cohort of women with similar CVD risk factors, higher baseline hsCRP is positively associated with carotid plaque progression in HIV-uninfected, but not HIV-infected, women, suggesting that subclinical CVD pathogenesis may be different HIV-infected women.
Authors: Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2015-07-17 Impact factor: 4.177
Authors: David B Hanna; Wendy S Post; Jennifer A Deal; Howard N Hodis; Lisa P Jacobson; Wendy J Mack; Kathryn Anastos; Stephen J Gange; Alan L Landay; Jason M Lazar; Frank J Palella; Phyllis C Tien; Mallory D Witt; Xiaonan Xue; Mary A Young; Robert C Kaplan; Lawrence A Kingsley Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Damiano Baldassarre; Arienne De Jong; Mauro Amato; J Pablo Werba; Samuela Castelnuovo; Beatrice Frigerio; Fabrizio Veglia; Elena Tremoli; Cesare R Sirtori Journal: Ann Med Date: 2008 Impact factor: 4.709
Authors: Julie A Womack; Chung-Chou H Chang; Kaku A So-Armah; Charles Alcorn; Jason V Baker; Sheldon T Brown; Matthew Budoff; Adeel A Butt; Cynthia Gibert; Matthew Bidwell Goetz; John Gottdiener; Stephen Gottlieb; Amy C Justice; David Leaf; Kathleen McGinnis; David Rimland; Maria C Rodriguez-Barradas; Jason Sico; Melissa Skanderson; Hilary Tindle; Russell P Tracy; Alberta Warner; Matthew S Freiberg Journal: J Am Heart Assoc Date: 2014-10-16 Impact factor: 5.501
Authors: Nicholas S Downing; Nilay D Shah; Joseph H Neiman; Jenerius A Aminawung; Harlan M Krumholz; Joseph S Ross Journal: Trials Date: 2016-04-14 Impact factor: 2.279
Authors: Lauren F Collins; Anandi N Sheth; C Christina Mehta; Susanna Naggie; Elizabeth T Golub; Kathryn Anastos; Audrey L French; Seble Kassaye; Tonya N Taylor; Margaret A Fischl; Adaora A Adimora; Mirjam-Colette Kempf; Frank J Palella; Phyllis C Tien; Ighovwerha Ofotokun Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Mohamed El-Far; David B Hanna; Madeleine Durand; Etienne Larouche-Anctil; Mohamed Sylla; Carl Chartrand-Lefebvre; Guy Cloutier; Jean Philippe Goulet; Seble Kassaye; Roksana Karim; Jorge R Kizer; Audrey L French; Stephen J Gange; Jason M Lazar; Howard N Hodis; Jean-Pierre Routy; Petronela Ancuta; Nicolas Chomont; Alan L Landay; Robert C Kaplan; Cécile L Tremblay Journal: J Acquir Immune Defic Syndr Date: 2021-10-01 Impact factor: 3.771